This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. Luxury electric vehicle maker Lucid Motors opened a manufacturing plant in Saudi Arabia two years ago in part to fulfill a major purchase order with the country. Now, the facility may serve another purpose: avoiding American tariffs. Speaking at the UBS Global Industrials and Transportation Conference in Florida on Wednesday, Lucid Motors CFO Taoufiq Boussaid said his Newark ...

Core Viewpoint - The article emphasizes that reshoring manufacturing in the U.S. is heavily dependent on the availability of skilled workers, suggesting that without a skilled workforce, the efforts to bring manufacturing back will be ineffective [1] Group 1: Skilled Workforce - The current shortage of skilled workers is a significant barrier to reshoring manufacturing [1] - Companies are facing challenges in finding employees with the necessary technical skills to operate advanced manufacturing technologies [1] - The need for investment in education and training programs is highlighted as essential for developing a skilled workforce [1] Group 2: Manufacturing Trends - There is a growing trend among companies to consider reshoring as a strategy to mitigate supply chain risks [1] - The article points out that while reshoring is a priority, it cannot be achieved without addressing the skills gap [1] - The potential economic benefits of reshoring are contingent upon the ability to fill skilled positions within the manufacturing sector [1]

Core Viewpoint - Newell Brands has made significant strides in re-shoring the production of Sharpie markers to the U.S., investing $2 billion in manufacturing efficiency, but faced disappointing Q3 earnings results leading to a sharp decline in stock price [1][2][4]. Group 1: Manufacturing and Production - Newell Brands has successfully re-shored nearly all Sharpie production to the U.S., specifically in Tennessee, producing all 97 colors domestically [1]. - The company invested $2 billion in manufacturing efficiency to facilitate this transition [1]. Group 2: Financial Performance - In Q3, Newell reported adjusted earnings of $0.17 per share, missing Wall Street's expectation of $0.18, and revenue of $1.8 billion, below the anticipated $1.9 billion [2][5]. - Sales declined by 7% year over year, and gross profit margin decreased by 80 basis points, although operating profit margin improved [5]. - The company earned only $0.05 per share on a GAAP basis, indicating that the adjusted profit was not reflective of actual performance [5]. Group 3: Future Outlook - CEO Chris Peterson expressed optimism for improvement in both domestic and international markets, projecting Q4 sales declines to be between 1% and 4% [6]. - Non-GAAP earnings for Q4 are expected to range from $0.16 to $0.20, which still falls short of the $0.27 that Wall Street anticipates [6][8].

Core Insights - Orion Group Holdings, Inc. reported strong financial results for Q3 2025, with a focus on revenue growth, cash generation, and strategic advancements [2][3][5] Financial Performance - Revenue for Q3 2025 was $225.1 million, slightly down from $226.7 million in Q3 2024 but up 10% sequentially from $205.3 million in Q2 2025 [4][7] - GAAP Net Income was $3.3 million, or $0.08 per diluted share, compared to $4.3 million, or $0.12 per diluted share in Q3 2024 [9] - Adjusted EBITDA for Q3 2025 was $13.1 million, down from $15.2 million in Q3 2024 but up 19% from $11.0 million in Q2 2025 [10] - Gross profit increased to $29.8 million, up 10% from $27.1 million in Q3 2024 [8] Operational Highlights - The company generated robust cash flow from operations of $23 million and free cash flow of $14 million, attributed to effective working capital management [5] - Booked awards and change orders totaled $160 million in the quarter, indicating strong demand [5] - The company expanded its bonding capacity by $400 million, enhancing its ability to bid on larger projects [14] Guidance and Outlook - Orion raised its full-year 2025 guidance for revenue to a range of $825 million to $860 million, adjusted EBITDA to $44 million to $46 million, and adjusted EPS to $0.18 to $0.22 [6] - The favorable outlook is supported by growing tailwinds in AI investment, reshoring manufacturing, marine infrastructure investment, and defense expansion [3] Backlog and Market Position - As of September 30, 2025, the total backlog was $679 million, with significant contributions from both Marine and Concrete segments [11] - Recent awards included projects for the U.S. Army Corps of Engineers and various commercial facilities, showcasing the company's diverse project portfolio [11] Balance Sheet and Cash Flow - Current assets as of September 30, 2025, were $269.7 million, with total debt outstanding at $23.6 million [12] - The company closed the sale of its East and West Jones property for $23.5 million, with proceeds expected to reduce debt and support corporate purposes [15]

Core Viewpoint - Philips is investing over $150 million in U.S. manufacturing and R&D to enhance AI-powered health technology production, aligning with the U.S. government's goal of reducing reliance on foreign goods [1][5]. Investment Details - The investment includes expanding the Reedsville, Pennsylvania manufacturing facility for AI-enabled ultrasound systems and the image-guided therapy facility in Plymouth, Minnesota [2]. - Additional funds will support various manufacturing and R&D projects over the coming years to bolster the company's growth in the U.S. [2]. Job Creation - The expansion of the Reedsville site is projected to create 120 skilled manufacturing jobs, while the Plymouth facility's expansion will include a new medtech training center expected to generate over 150 new jobs [9]. Existing Operations - Philips has a significant presence in the U.S. with nearly 17,000 employees across 40 facilities, contributing to innovations used in 90% of hospitals nationwide [5]. Broader Context - The investment aligns with the Trump administration's efforts to boost domestic manufacturing, which has seen commitments exceeding $8 trillion from various companies since the election [12]. - The reshoring of manufacturing faces challenges such as high labor costs and a shortage of skilled workers, but the U.S. benefits from abundant energy resources and potential advancements in automation [13][15].

Core Viewpoint - Eli Lilly's CEO David Ricks emphasizes the company's readiness to address national security concerns related to the importation of essential medicines, particularly in light of potential pharmaceutical tariffs being considered by the Trump administration [1][2][3]. Group 1: National Security and Tariffs - The Trump administration has initiated a Section 232 investigation regarding the impact of drug imports on national security, potentially leading to tariffs on pharmaceuticals [2]. - Ricks acknowledges the validity of national security concerns regarding older generic drugs, which constitute about 90% of prescribed medicines in the U.S. [3]. - Ricks expresses uncertainty about whether tariffs are the appropriate solution to these concerns, suggesting that Eli Lilly is open to discussions with the administration on how to respond to potential crises [3][4]. Group 2: Manufacturing and Investment - Eli Lilly plans to invest at least $27 billion to establish four new production sites in the U.S., indicating a proactive approach to domestic manufacturing in response to tariff threats [5]. - Ricks notes that the threat of tariffs is already prompting a resurgence of critical supply chains in industries such as pharmaceuticals [6]. - The company advocates for permanent lower tax rates for domestic production, suggesting that economic incentives could encourage drugmakers to return manufacturing to the U.S. from low-tax countries [6].

Group 1: Investment and Manufacturing Expansion - Eli Lilly is investing an additional $27 billion to enhance domestic drug production, bringing its total U.S. manufacturing investment to over $50 billion since 2020 [1][2] - The company plans to build four new pharmaceutical manufacturing sites, with three focusing on active pharmaceutical ingredients to strengthen its supply chain [2] - The investment will create 3,000 jobs for skilled workers and support 10,000 construction jobs [5] Group 2: Strategic Vision and Market Position - Eli Lilly's CEO, David Ricks, expressed optimism about the company's pipeline across various therapeutic areas, which drives the commitment to domestic manufacturing [4] - The investment reflects the company's strategy to meet anticipated demand for safe, high-quality, FDA-approved medicines in the future [5] Group 3: Industry Context - The announcement comes amid U.S. plans to impose tariffs on Canada and Mexico, which may impact the broader manufacturing landscape [7][8] - Eli Lilly's investment aligns with a trend of companies committing to U.S. manufacturing under the current administration, with Apple also announcing a significant $500 billion investment [9]

Core Viewpoint - Eli Lilly plans to invest at least $27 billion to establish four new manufacturing sites in the U.S. to meet the rising demand for its weight loss and diabetes medications, while also developing new drugs for other conditions [1][3]. Investment and Manufacturing Expansion - The new investment will increase Eli Lilly's total U.S. manufacturing investments to over $50 billion in recent years, with $23 billion allocated to new plants and site expansions since 2020 [3]. - Three of the new sites will focus on manufacturing active ingredients for medications, including tirzepatide, which is used in Eli Lilly's obesity drug Zepbound and diabetes treatment Mounjaro [3][4]. - The fourth site will enhance the company's global manufacturing network for future injectable therapies [4]. Strategic Context - The announcement aligns with broader industry efforts to build goodwill with the U.S. government, particularly under President Donald Trump's emphasis on reshoring manufacturing and reducing foreign supply chain reliance [2]. - Eli Lilly's CEO highlighted the company's commitment to domestic manufacturing as a response to anticipated demand for safe, high-quality FDA-approved medicines [5][7]. Market Dynamics - Eli Lilly's investments are driven by the success of Zepbound and Mounjaro, which compete in the growing GLP-1 drug market alongside Novo Nordisk's products [6]. - Analysts project that the global obesity drug market could exceed $150 billion annually by the early 2030s, making it crucial for Eli Lilly to maintain its market share [6]. Supply Chain and Regulatory Environment - The company aims to ensure that patients have access to its branded treatments rather than unapproved compounded versions, which became popular during previous supply shortages [7]. - The FDA has declared the shortage of tirzepatide over, which will limit the ability of compounding pharmacies to produce copycat versions [8].